The place of Zoladex(R) in deferred surgery for uterine fibroids
The place of Zoladex(R) in deferred surgery for uterine fibroids
复制标题
DOI：
10.1159/000184806
复制
发表时间：
1996-06-01
期刊：
影响因子：
--
通讯作者：
Dalton, E
中科院分区：
文献类型：
--
作者：
Gerris, J;Degueldre, M;Dalton, E
247例子宫肌瘤患者被随机分为单独手术组和服用3个月唑拉德(R)组（Zeneca, Macclesfield, Ches）。（英国），然后进行手术。唑拉地克显著减少子宫和肌瘤体积（p = 0.0001）。与单纯手术组（0.3 g/dl）相比，Zoladex组从入组到术前血红蛋白的平均升高（1 g/dl）显著（p = 0.002），而且更容易手术，手术失血量减少。该组患者的住院时间明显缩短（p = 0.016），盆腔疼痛和腹压症状明显减轻（p < 0.0001）。Zoladex耐受性良好。
Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months' Zoladex(R) (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group (0.3 g/dl) as well as a tendency towards easier surgery, and reduced operative blood loss. Zoladex-treated patients had a significantly (p = 0.016) shorter hospital stay and pelvic pain and abdominal pressure symptoms were significantly (p < 0.0001) reduced in this group. Zoladex was well tolerated.